Wendel Naumann R, et al. - Among patients with high grade ovarian cancer who received adjuvant intraperitoneal (IP) chemotherapy in the initial setting between 2005 and 2016, researchers assessed the outcomes between those with vs without pathogenic BRCA mutations. According to findings, in optimally resected ovarian cancer patients selected for IP therapy, pathogenic BRCA mutations were more commonly detected than anticipated. In BRCA+ patients vs BRCA− patients, a dramatic improvement in progression-free survival (PFS) and overall survival (OS) was seen in association with IP therapy, and this was greater than the improvement reported for BRCA+ patients with IV chemotherapy. Considering the degree of this benefit, IP therapy may be beneficial in patients with pathogenic mutations in BRCA.